By Sheri Kasprzak
New York, April 25 - Innovive Pharmaceuticals, Inc. closed a $15.015 million private placement.
The company sold 5.5 million units at $2.73 each.
The units are comprised of one share and one half-share warrant. Each whole warrant is exercisable at $3.75 for five years.
Paramount BioCapital Inc. was the placement agent.
Proceeds will be used for the advancement of the company's pipeline of hematology and oncology products.
New York-based Innovive acquires, develops and commercializes therapies for cancer and blood diseases.
| Issuer: | Innovive Pharmaceuticals, Inc.
|
| Issue: | Units of one share and one half-share warrant
|
| Amount: | $15.015 million
|
| Units: | 5.5 million
|
| Price: | $2.73
|
| Warrants: | One half-share warrant per unit
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $3.75
|
| Placement agent: | Paramount BioCapital Inc.
|
| Settlement date: | April 24
|
| Stock symbol: | OTCBB: IVPH
|
| Stock price: | $3.50 at close April 24
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
